{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T18:47:09Z","timestamp":1780426029908,"version":"3.54.1"},"reference-count":35,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2011,6,1]],"date-time":"2011-06-01T00:00:00Z","timestamp":1306886400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2011,6,1]],"date-time":"2011-06-01T00:00:00Z","timestamp":1306886400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2013,8,22]],"date-time":"2013-08-22T00:00:00Z","timestamp":1377129600000},"content-version":"vor","delay-in-days":813,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","resmedjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Respiratory Medicine"],"published-print":{"date-parts":[[2011,6]]},"DOI":"10.1016\/j.rmed.2011.02.013","type":"journal-article","created":{"date-parts":[[2011,3,16]],"date-time":"2011-03-16T16:29:57Z","timestamp":1300292997000},"page":"892-899","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"title":["Profiling the effects of indacaterol on dyspnoea and health status in patients with COPD"],"prefix":"10.1016","volume":"105","author":[{"given":"Paul W.","family":"Jones","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donald A.","family":"Mahler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rupert","family":"Gale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger","family":"Owen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Kramer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.rmed.2011.02.013_bib1","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1080\/15412550701480265","article-title":"Activity limitation and quality of life in COPD","volume":"4","author":"Jones","year":"2007","journal-title":"COPD"},{"key":"10.1016\/j.rmed.2011.02.013_bib2","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1164\/ajrccm.164.5.2007006","article-title":"Inhaled formoterol dry powder versus ipratropium bromide in chronic obstructive pulmonary disease","volume":"164","author":"Dahl","year":"2001","journal-title":"Am J Respir Crit Care Med"},{"issue":"6 Suppl.","key":"10.1016\/j.rmed.2011.02.013_bib3","doi-asserted-by":"crossref","first-page":"S298","DOI":"10.1067\/mai.2002.129703","article-title":"The effect of inhaled beta2-agonists on clinical outcomes in chronic obstructive pulmonary disease","volume":"110","author":"Mahler","year":"2002","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.rmed.2011.02.013_bib4","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1136\/thx.2006.063271","article-title":"Tiotropium for stable chronic obstructive pulmonary disease: a meta-analysis","volume":"61","author":"Barr","year":"2006","journal-title":"Thorax"},{"key":"10.1016\/j.rmed.2011.02.013_bib5","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1517\/13543784.14.7.775","article-title":"Ultra long-acting beta 2-agonists in development for asthma and chronic obstructive pulmonary disease","volume":"14","author":"Cazzola","year":"2005","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.rmed.2011.02.013_bib6","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1136\/thx.2009.125435","article-title":"Efficacy of a new once-daily LABA, indacaterol, versus the twice-daily LABA, formoterol, in COPD","volume":"65","author":"Dahl","year":"2010","journal-title":"Thorax"},{"key":"10.1016\/j.rmed.2011.02.013_bib7","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1164\/rccm.200910-1500OC","article-title":"Once-daily bronchodilators for chronic obstructive pulmonary disease: indacaterol versus tiotropium","volume":"182","author":"Donohue","year":"2010","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.rmed.2011.02.013_bib8","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1183\/09031936.00045810","article-title":"Once-daily indacaterol vs twice-daily salmeterol for COPD: a placebo-controlled comparison","volume":"37","author":"Kornmann","year":"2011","journal-title":"Eur Respir J"},{"key":"10.1016\/j.rmed.2011.02.013_bib9","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/1471-2466-10-11","article-title":"Efficacy and safety of indacaterol 150\u00a0\u03bcg once-daily in COPD: a double-blind, randomised, 12-week study","volume":"10","author":"Feldman","year":"2010","journal-title":"BMC Pulm Med"},{"key":"10.1016\/j.rmed.2011.02.013_bib10","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1183\/09031936.06.00145104","article-title":"Outcomes and markers in the assessment of chronic obstructive pulmonary disease","volume":"27","author":"Jones","year":"2006","journal-title":"Eur Respir J"},{"key":"10.1016\/j.rmed.2011.02.013_bib11","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1378\/chest.85.6.751","article-title":"The measurement of dyspnea. Contents, interobserver agreement, and physiologic correlates of two new clinical indexes","volume":"85","author":"Mahler","year":"1984","journal-title":"Chest"},{"key":"10.1016\/j.rmed.2011.02.013_bib12","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1164\/ajrccm\/145.6.1321","article-title":"A self-complete measure of health status for chronic airflow limitation. The St. George\u2019s respiratory questionnaire","volume":"145","author":"Jones","year":"1992","journal-title":"Am Rev Respir Dis"},{"key":"10.1016\/j.rmed.2011.02.013_bib13","unstructured":"Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. Updated 2005. At: http:\/\/www.goldcopd.com\/GuidelineItem.asp?intId=1386."},{"key":"10.1016\/j.rmed.2011.02.013_bib14","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1081\/COPD-200050666","article-title":"The MCID of the transition dyspnea index is a total score of one unit","volume":"2","author":"Mahler","year":"2005","journal-title":"COPD"},{"key":"10.1016\/j.rmed.2011.02.013_bib15","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/S0895-4356(02)00589-9","article-title":"Meaningful effect size and patterns of response of the transition dyspnea index","volume":"56","author":"Witek","year":"2003","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.rmed.2011.02.013_bib16","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1183\/09031936.03.00068503a","article-title":"Minimal important difference of the transition dyspnoea index in a multinational clinical trial","volume":"21","author":"Witek","year":"2003","journal-title":"Eur Respir J"},{"key":"10.1016\/j.rmed.2011.02.013_bib17","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1081\/COPD-200050513","article-title":"St. George\u2019s respiratory questionnaire: MCID","volume":"2","author":"Jones","year":"2005","journal-title":"COPD"},{"key":"10.1016\/j.rmed.2011.02.013_bib18","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1513\/pats.200509-103SF","article-title":"Mechanisms and measurement of dyspnea in chronic obstructive pulmonary disease","volume":"3","author":"Mahler","year":"2006","journal-title":"Proc Am Thorac Soc"},{"key":"10.1016\/j.rmed.2011.02.013_bib19","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/j.rmed.2005.09.011","article-title":"Measuring the effects of COPD on the patient","volume":"99","author":"Jones","year":"2005","journal-title":"Respir Med"},{"key":"10.1016\/j.rmed.2011.02.013_bib20","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1136\/thorax.56.11.880","article-title":"Health status measurement in chronic obstructive pulmonary disease","volume":"56","author":"Jones","year":"2001","journal-title":"Thorax"},{"key":"10.1016\/j.rmed.2011.02.013_bib21","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1183\/09031936.00099306","article-title":"Outcomes for COPD pharmacological trials: from lung function to biomarkers","volume":"31","author":"Cazzola","year":"2008","journal-title":"Eur Respir J"},{"key":"10.1016\/j.rmed.2011.02.013_bib22","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1183\/09031936.02.00269802","article-title":"A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease","volume":"19","author":"Casaburi","year":"2002","journal-title":"Eur Respir J"},{"key":"10.1016\/j.rmed.2011.02.013_bib23","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1136\/thorax.58.5.399","article-title":"Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD","volume":"58","author":"Brusasco","year":"2003","journal-title":"Thorax"},{"key":"10.1016\/j.rmed.2011.02.013_bib24","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1378\/chest.122.1.47","article-title":"A 6-month, placebo-controlled study comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterol","volume":"122","author":"Donohue","year":"2002","journal-title":"Chest"},{"key":"10.1016\/j.rmed.2011.02.013_bib25","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1378\/chest.115.4.957","article-title":"Efficacy of salmeterol xinafoate in the treatment of COPD","volume":"115","author":"Mahler","year":"1999","journal-title":"Chest"},{"key":"10.1016\/j.rmed.2011.02.013_bib26","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1378\/chest.124.3.834","article-title":"The efficacy and safety of fluticasone propionate (250\u00a0\u03bcg)\/salmeterol (50\u00a0\u03bcg) combined in the Diskus inhaler for the treatment of COPD","volume":"124","author":"Hanania","year":"2003","journal-title":"Chest"},{"key":"10.1016\/j.rmed.2011.02.013_bib27","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1378\/chest.119.6.1661","article-title":"Salmeterol plus theophylline combination therapy in the treatment of COPD","volume":"119","author":"ZuWallack","year":"2001","journal-title":"Chest"},{"key":"10.1016\/j.rmed.2011.02.013_bib28","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/S0140-6736(03)12459-2","article-title":"Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial","volume":"361","author":"Calverley","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.rmed.2011.02.013_bib29","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1164\/ajrccm.155.4.9105068","article-title":"Changes in quality of life in COPD patients treated with salmeterol","volume":"155","author":"Jones","year":"1997","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.rmed.2011.02.013_bib30","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1136\/thx.2004.033266","article-title":"Addition of salmeterol to existing treatment in patients with COPD: a 12 month study","volume":"61","author":"Stockley","year":"2006","journal-title":"Thorax"},{"key":"10.1016\/j.rmed.2011.02.013_bib31","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1378\/chest.09-0934","article-title":"Patient-reported dyspnea in COPD reliability and association with stage of disease","volume":"136","author":"Mahler","year":"2009","journal-title":"Chest"},{"key":"10.1016\/j.rmed.2011.02.013_bib32","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1378\/chest.09-2498","article-title":"Affective descriptors of the sensation of breathlessness are more highly associated with severity of impairment than physical descriptors in people with chronic obstructive pulmonary disease","volume":"138","author":"Williams","year":"2010","journal-title":"Chest"},{"key":"10.1016\/j.rmed.2011.02.013_bib33","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1378\/chest.07-2916","article-title":"The language of breathlessness differentiates between patients with COPD and age-matched adults","volume":"134","author":"Williams","year":"2008","journal-title":"Chest"},{"key":"10.1016\/j.rmed.2011.02.013_bib34","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1378\/chest.124.4.1350","article-title":"Withdrawal from treatment as an outcome in the ISOLDE study of COPD","volume":"124","author":"Calverley","year":"2003","journal-title":"Chest"},{"key":"10.1016\/j.rmed.2011.02.013_bib35","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1164\/rccm.200707-973OC","article-title":"The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol\/fluticasone propionate or tiotropium bromide","volume":"177","author":"Wedzicha","year":"2008","journal-title":"Am J Respir Crit Care Med"}],"container-title":["Respiratory Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S095461111100062X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S095461111100062X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T11:13:20Z","timestamp":1760613200000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S095461111100062X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,6]]},"references-count":35,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2011,6]]}},"alternative-id":["S095461111100062X"],"URL":"https:\/\/doi.org\/10.1016\/j.rmed.2011.02.013","relation":{},"ISSN":["0954-6111"],"issn-type":[{"value":"0954-6111","type":"print"}],"subject":[],"published":{"date-parts":[[2011,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Profiling the effects of indacaterol on dyspnoea and health status in patients with COPD","name":"articletitle","label":"Article Title"},{"value":"Respiratory Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rmed.2011.02.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2011 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}